Synthesis, Characterization, Molecular Docking and in vitro Biological Studies of Thiazolidin‐4‐one Derivatives as Anti‐Breast‐Cancer Agents
In this study, 16 new compounds were synthesized starting from methylparaben. These new
compounds consist of eight arylidenehydrazide derivatives and eight thiazolidin‐4‐on
derivatives. All compounds were tested against MCF‐7 breast cancer cells and MCF10A
breast healthy tissue to determine their anti‐cancer activity. Molecular docking studies were
also carried out against receptor proteins related to the growth factor of cancer cells to
understand inhibition mechanism. According to the results, 4‐furan‐2‐ylmethoxy)‐N‐(4‐oxo …
compounds consist of eight arylidenehydrazide derivatives and eight thiazolidin‐4‐on
derivatives. All compounds were tested against MCF‐7 breast cancer cells and MCF10A
breast healthy tissue to determine their anti‐cancer activity. Molecular docking studies were
also carried out against receptor proteins related to the growth factor of cancer cells to
understand inhibition mechanism. According to the results, 4‐furan‐2‐ylmethoxy)‐N‐(4‐oxo …
Abstract
In this study, 16 new compounds were synthesized starting from methylparaben. These new compounds consist of eight arylidenehydrazide derivatives and eight thiazolidin‐4‐on derivatives. All compounds were tested against MCF‐7 breast cancer cells and MCF10A breast healthy tissue to determine their anti‐cancer activity. Molecular docking studies were also carried out against receptor proteins related to the growth factor of cancer cells to understand inhibition mechanism. According to the results, 4‐furan‐2‐ylmethoxy)‐N‐(4‐oxo‐2‐phenylthiazolidin‐3‐yl)benzamide (5 a) and 4‐(furan‐2‐ylmethoxy)‐N‐(2‐(4‐nitrophenyl)‐4‐oxothiazolidin‐3‐yl)benzamide (5 e) were found as the highest selective and most active compounds against breast cancer cells.
Wiley Online Library